American College of Cardiology

FEBRUARY 1, 2025

Cardiovascular medications frequently lead this category, often contributing to adverse clinical outcomes, including emergency department visits and hospitalizations. Common cardiovascular ADRs in geriatric patients include acute kidney injury, bleeding and orthostatic hypotension which can lead to hospitalization.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40

GEMMS

APRIL 8, 2024

Established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) , the MIPS Program is pivotal in determining Medicare payment adjustments for healthcare practices. What is MIPS? Additionally, the 2024 final rule retains the methodology for measuring scores and achieving points with no notable alterations.

Medicare 52

Medicare Innovation Medicaid Patient Care 52

Vector Remote

JUNE 30, 2023

Consider plugging the monitor at the hospital bedside to eliminate the need for an in-person interrogation and expedite patient discharge. Actionable Step: Prior to the implant, educate patients about remote monitoring. After implant, pair the monitor for the initial transmission.

Heart Rhythm 52

Heart Rhythm Education Patient Care Technology 52

Vector Remote

MARCH 9, 2023

Cardiac devices managed by RPM software are reducing hospital admissions and time to diagnosis and treatment for patients with arrhythmias and heart failure. What’s Next in Cardiac Remote Patient Monitoring Software ?

Heart Failure 52

Heart Failure Patient Care Heart Rhythm Hypertension 52

DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by CMS for both treatment and control procedures.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

MARCH 7, 2024

Despite improvements with current medications and devices, heart failure remains at epidemic proportions and we now have an exciting opportunity for a therapy to improve important, objective outcomes, such as mortality and hospital re-admissions rates. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

DAIC

JULY 25, 2024

“The CardiAMP cell therapy has the potential to be groundbreaking and life changing for patients with heart failure,” said Dr. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

Dr. Anish Koka

JULY 23, 2023

Vascular surgeons at nearby hospitals had complained because they were seeing “a lot” of his patients having complications. There have been many more attempts to open arteries that have taken place in private clinics since reimbursement rules changed. A thrombolysis is performed in the hospital via a catheter.

Vascular Care 52

Vascular Care Outpatient Peripheral Arterial Disease Stents 52

DAIC

MARCH 3, 2025

Dr. Mouaz Al-Mallah, MD, MSc, MASNC, Director of Cardiac PET at Houston Methodist Hospital, said, Flyrcado opens new frontiers for cardiac PET with a significantly longer half-life than existing PET MPI tracers, and we are proud to be one of the first to use it in our cardiac PET lab. National Center for Health Statistics.

Coronary Artery Disease 52

Coronary Artery Disease Exercise Ischemia Hospital 52